Despite significant advances in precision oncology, key oncoproteins such as Ras, MYC, and p53 remain historically difficult to drug. Conventional pharmacologic strategies are fundamentally constrained by their dependency on direct interactions with well-defin... ...

请注册登录后继续浏览